EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Histone‐Lysine N‐Methyltransferase (KMT2) Family in Health and Disease

Qiu Wang, Zunjie Bo, Ya Zhang, Yun Chen, Zhiyu Wang, Shuangmei Tong, Ajing Xu, Jian Zhang, Yan Liu iD

MedComm · 2026-04 · 7 (4)

DOI: 10.1002/mco2.70728 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 09.04.2026. Verfasst von Qiu Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 365 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Shanghai Municipal Health Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The histone‐lysine N‐methyltransferase (KMT2) family is a central epigenetic regulator whose dysfunction drives diverse human diseases through distinct molecular mechanisms. In acute leukemias, KMT2A rearrangements aberrantly recruit transcriptional cofactors, activating oncogenic gene programs; in solid tumors, loss‐of‐function mutations in KMT2C/D disrupt enhancer‐mediated regulatory networks, compromising cellular identity and genome stability; in neurodevelopmental disorders, germline haploinsufficiency of KMT2A/B/D impairs developmental epigenetic programming. Despite increasingly comprehensive understanding of the pathogenic mechanisms involving KMT2 family members, a unified framework translating these molecular insights into effective, subtype‐specific therapeutic strategies has been lacking. This review comprehensively deconstructs these pathogenic pathways and explores how mechanistic insights are being translated into novel therapeutic strategies, including direct targeting of oncogenic transcriptional complexes, exploiting vulnerabilities from tumor suppressor loss, and modulating the tumor immune microenvironment. We systematically synthesize recent clinical advances, from small‐molecule inhibitors against protein–protein interactions (e.g., menin–KMT2A), to targeted degraders (PROTACs), epigenetic readers/writers inhibitors (e.g., BET, LSD1, DOT1L), and rational combination regimens with chemotherapy or immunotherapy. By integrating the biological characteristics of KMT2 with translational medicine and clinical evidence, this study provides a framework for advancing precision medicine approaches based on the molecular subtypes driven by KMT2.

Schlagwörter

Stichwörter der Autor:innen

KMT2 familydiseaseepigeneticstherapy

Autor:innen und Institutionen

  • Department of Clinical Pharmacy Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai China.
  • Dalian Medical University Dalian China.
  • Department of Clinical Pharmacy Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Shanghai China.

ORCID-Profile: Yan Liu

Förderung

  • National Natural Science Foundation of China
  • Shanghai Municipal Health Commission

Zitieren

APA

Wang, Q., Bo, Z., Zhang, Y., Chen, Y., Wang, Z., Tong, S., Xu, A., Zhang, J., & Liu, Y. (2026). The Histone‐Lysine N‐Methyltransferase (KMT2) Family in Health and Disease. MedComm, 7(4). https://doi.org/10.1002/mco2.70728

Vancouver

Wang Q, Bo Z, Zhang Y, Chen Y, Wang Z, Tong S, et al. The Histone‐Lysine N‐Methyltransferase (KMT2) Family in Health and Disease. MedComm. 2026;7(4). doi:10.1002/mco2.70728

BibTeX
@article{Wang2026,
  author = {Wang, Qiu and Bo, Zunjie and Zhang, Ya and Chen, Yun and Wang, Zhiyu and Tong, Shuangmei and Xu, Ajing and Zhang, Jian and Liu, Yan},
  title = {The Histone‐Lysine N‐Methyltransferase (KMT2) Family in Health and Disease},
  journal = {MedComm},
  year = {2026},
  volume = {7},
  number = {4},
  doi = {10.1002/mco2.70728}
}
Kostenlos starten →